MetLife Investment Advisors LLC Takes Position in OraSure Technologies (OSUR)

MetLife Investment Advisors LLC acquired a new position in shares of OraSure Technologies (NASDAQ:OSUR) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 25,014 shares of the medical instruments supplier’s stock, valued at approximately $472,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. boosted its position in shares of OraSure Technologies by 2.7% during the fourth quarter. BlackRock Inc. now owns 7,729,515 shares of the medical instruments supplier’s stock worth $145,778,000 after buying an additional 201,251 shares during the period. Millennium Management LLC boosted its position in shares of OraSure Technologies by 87.9% during the fourth quarter. Millennium Management LLC now owns 1,624,216 shares of the medical instruments supplier’s stock worth $30,633,000 after buying an additional 759,958 shares during the period. Fred Alger Management Inc. acquired a new position in shares of OraSure Technologies during the fourth quarter worth approximately $20,415,000. Teachers Advisors LLC boosted its position in shares of OraSure Technologies by 9.0% during the fourth quarter. Teachers Advisors LLC now owns 965,464 shares of the medical instruments supplier’s stock worth $18,209,000 after buying an additional 79,886 shares during the period. Finally, RTW Investments LP boosted its position in shares of OraSure Technologies by 64.0% during the fourth quarter. RTW Investments LP now owns 878,452 shares of the medical instruments supplier’s stock worth $16,568,000 after buying an additional 342,745 shares during the period. Institutional investors and hedge funds own 92.86% of the company’s stock.

How to Become a New Pot Stock Millionaire

Several equities analysts have recently issued reports on the company. Zacks Investment Research upgraded OraSure Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. BidaskClub downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, April 3rd. ValuEngine upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday, March 2nd. Finally, Canaccord Genuity reiterated a “buy” rating and set a $24.00 price objective on shares of OraSure Technologies in a research report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. OraSure Technologies currently has a consensus rating of “Hold” and an average target price of $22.25.



OSUR opened at $17.18 on Friday. The company has a market capitalization of $1,079.22, a price-to-earnings ratio of 33.69, a PEG ratio of 4.93 and a beta of 1.65. OraSure Technologies has a 1-year low of $12.43 and a 1-year high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. The firm had revenue of $52.00 million during the quarter, compared to the consensus estimate of $50.20 million. OraSure Technologies had a return on equity of 13.09% and a net margin of 18.52%. The firm’s revenue for the quarter was up 46.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.13 earnings per share. equities analysts predict that OraSure Technologies will post 0.29 EPS for the current fiscal year.

In other OraSure Technologies news, EVP Brian Smith sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $17.97, for a total value of $359,400.00. Following the completion of the sale, the executive vice president now directly owns 28,075 shares in the company, valued at $504,507.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Stephen S. Phd Tang sold 23,333 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $17.97, for a total value of $419,294.01. Following the completion of the sale, the director now owns 59,749 shares of the company’s stock, valued at $1,073,689.53. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.

TRADEMARK VIOLATION WARNING: “MetLife Investment Advisors LLC Takes Position in OraSure Technologies (OSUR)” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2018/04/22/metlife-investment-advisors-llc-takes-position-in-orasure-technologies-osur.html.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies (NASDAQ:OSUR).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply